Targeted therapy of inflammatory bowel diseases: realities and prospects

Abstract

This review article was designed to systematize the literature data concerning the role of targeted therapy in the treatment of patients with inflammatory bowel diseases. It presents the data of the latest randomized clinical trials and meta-analyses evaluating the efficacy and safety of targeted drugs for the treatment of Crohn’s disease and ulcerative colitis.

Keywords

• inflammatory bowel disease
• crohn’s disease
• ulcerative colitis
• targeted therapy
• biological therapy
• infliximab
• adalimumab
• golimumab
• cetrolizumab
• tofacinib
• filgotinib
• ustkinumab
• natalizumab
• vedolizumab